Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-101 (Roche)
- Development stage
- Unknown
- Lead developer
- Serenity Bioworks
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SER-101 (RO1160367) is an orally administered small-molecule selective antagonist of the serotonin 4 (5-HT4) receptor that was originally discovered and developed by Roche and subsequently in-licensed by Serodus for cardiovascular indications, particularly congestive heart failure. By blocking 5-HT4 receptor–mediated signaling, SER-101 is intended to modulate maladaptive serotonergic effects on cardiac structure and function that contribute to heart failure progression, and it has been evaluated in early-phase clinical development as a novel, mechanism-based therapy for heart failure and related cardiovascular disease.[3][5][7][8][11][13]
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on SER-101 (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-101 (Roche).